My 'Eye' Is On Tarsus Pharmaceuticals

Impact · against what's priced in

TARS shows potential upside based on a combined blockbuster trajectory for Xdemvy and the acquired IRX-101. While the commercial ramp is strong, the current valuation likely reflects these peak sales targets, making the recent 18% pullback the primary driver for new entry interest rather than fundamentally new catalysts.

TARS+0.40

No priced-in read yet

In context

The company's $3.3B market cap is supported by Xdemvy's $2B peak sales potential and the addition of IRX-101, which adds another $600–900M in estimated peak sales.

Read from the article alone

• valuation
• biotech
• TARS
• acquisitions
• drug approval
• ophthalmology
• pharmaceuticals
• pipeline

Search tags